News

Doug Manion, CEO of Kleo, explains how platform technology essentially involves the engineering of antibodies and biologics using linear process chemistry to enhance drug effectiveness.

CISCRP – in partnership with 10 leading pharmaceutical companies and clinical research service providers – has launched a new consortium that will focus energy and resources on community-based education to improve clinical trial diversity.

How sharing patient data drives trial engagement and honors patient contributions to the research process.

Centralized monitoring offers sponsors and CROs the program-wide oversight they need to successfully develop the medications of the future, says CluePoints CEO, Francois Torche.

Do users actually want to use Excel? Explore the different viewpoints behind choosing SaaS or Excel.

Dr. Riam Shammaa of INTELLiSTEM discusses his discoveries, how he plans to tackle clinical trial and therapy development challenges, and what the future development of cell-gene based cancer treatments look like.

The shift from paper to cloud-based regulatory information management systems (RIMS) to address operations challenges.

A compilation of recently released news briefs that pertain to the clinical trials industry.

How one biotech is tackling the unmet need for additional immunotherapies and combination approaches in cancer.

A new era for clinical trials supply compliance in the EU is almost here.

The long-running SEND initiative has fostered new FDA-industry partnerships, opening the door to dramatic changes in toxicology data analysis.

Click the title above to open the Applied Clinical Trials December 2019 issue in an interactive PDF format.

Some thoughts around the industry continuing to grapple with the high price tag associated with drug development costs.

Outlining the nation’s key changes and current requirements in processing investigational and new drug applications.

Why and how FDA is funding a digital biomarkers study that centers on quality of life for patients with heart failure.

A view of the notable policy strategies advanced in 2019 to boost drug development and review.

Peter O’Donnell explores where the EU stands today in R&D pursuits for new antibacterial therapies.